South Korean artificial intelligence (AI) developer VUNO Inc. joined the first batch of innovative medical device companies certified by the Ministry of Health and Welfare (MOHW) on Dec. 1, being categorized as an innovative takeoff-type business.
As the soaring exports of South Korean COVID-19 test kits led to a growing interest in the medical device industry, the MOHW launched a project to pick out a group of innovative medical device companies which have the potential to lead the medical device industry based on technological innovative capability, industry-specific specialty and expertise. The top 30 companies were selected by the ministry among a total of 102 applicants, highly acknowledged for their competence in medical device research & development and global competitiveness.
Widely renowned as a pioneering startup for its unprecedented success in making deep learning available on the South Korean medical IT industry, VUNO wrote a new chapter of its history by rolling out the nation's first medical AI solution VUNO Med®-BoneAge™ in 2018. VUNO enables comprehensive data analysis, including medical imaging including X-ray, CT, MRI, and fundus images, biosignal, pathology images and speech, and uses its extensive experience in multi-modal analyses & technologies, Putting work efficiency and accuracy in clinical medicine first and foremost, VUNO is always enthusiastic about developing and putting various medical AI software programs to clinical use. It has been graining great traction at home and abroad with more than 200 active users of hospitals and is ready to deploy the CE marked products to international business partners and clients across different markets.
In July, VUNO Med®-Fundus AI™ set a remarkable milestone by becoming the first innovative medical device in South Korea. It analyzes retinal fundus images to detect 12 abnormal lesions and classifies them for diagnosis. The 12 findings detected by the device are an all–encompassing set of medical information that is crucial to diagnosing a wide range of retinal diseases including diabetic retinopathy, macular degeneration and glaucoma.
Furthermore, Med®-DeepCARS™ also designated as an innovative medical device. It is the first bio-signal-based AI medical device to receive a regulatory green light from the Ministry of Food and Drug Safety (MFDS) on conducting clinical trials. The software predicts the risk of cardiac arrest occurring within the next 24 hours by doing an analysis of vital signs including pulse, respiratory rate, blood pressure and body temperature.